anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A post-chemical intake glutamate pyruvate transaminase indicator comprising: glutamic-pyruvic transaminase value, time information and detection group information. The glutamate pyruvate transaminase value and time information is a collection of readings of a glutamate pyruvate transaminase value test taken at a time after ingestion or/and after a meal, including time information. The test group information includes average information obtained by tracking how many test individuals in total, and the species of the test individuals. The invention provides a method for quantifying glutamic-pyruvic transaminase index after intake of an ingested chemical substance, which can be used for discovering the interference of the components on the glutamic-pyruvic transaminase of a human body by statistics before the delivery of a medicine, food or food additive. The present invention provides a statistical method of glutamate pyruvate transaminase after chemical intake to detect or statistically or roughly show damage to the liver after chemical intake. The present invention can be written on the instruction sheet of the medicine or food or additive to let a person evaluate hepatotoxicity in general.
Extreme care must be used in administering injectable diazepam to the elderly, to very ill patients and to those with limited pulmonary reserve because of the possibility that apnea and/or cardiac arrest may occur. Concomitant use of barbiturates, alcohol, or other central nervous system depressants increases depression with increased risk of apnea. Resuscitative equipment including that necessary to support respiration should be readily available.

When diazepam is used with a narcotic analgesic, the dosage of the narcotic should be reduced by at least one-third and administered in small increments. In some cases the use of a narcotic may not be necessary (see PRECAUTIONS).

Diazepam injection should not be administered to patients in shock, coma, or in acute alcoholic intoxication with depression of vital signs. As is true of most CNS-acting drugs, patients receiving diazepam should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.
Group (1): Patients will be treated with Keratin cure ® hair treatment. It will be applied once with use of a flat iron.
OBJECTIVE: This study aimed to analyze the features of resting-state functional magnetic resonance imaging (rs-fMRI) and clinical relevance in patients with benign paroxysmal positional vertigo (BPPV) that have undergone repositioning maneuvers.
METHODS: A total of 38 patients with BPPV who have received repositioning maneuvers and 38 matched healthy controls (HCs) were enrolled in the present study from March 2018 to August 2021. Imaging analysis software was employed for functional image preprocessing and indicator calculation, mainly including the amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF), percent amplitude of fluctuation (PerAF), and seed-based functional connectivity (FC). Statistical analysis of the various functional indicators in patients with BPPV and HCs was also conducted, and correlation analysis with clinical data was performed.
RESULTS: Patients with BPPV displayed decrease in ALFF, fALFF, and PerAF values, mainly in the bilateral occipital lobes in comparison with HCs. Additionally, their ALFF and fALFF values in the proximal vermis region of the cerebellum increased relative to HCs. The PerAF values in the bilateral paracentral lobules, the right supplementary motor area (SMA), and the left precuneus decreased in patients with BPPV and were negatively correlated with dizziness visual analog scale (VAS) scores 1 week after repositioning (W1). In addition, in the left fusiform gyrus and lingual gyrus, the PerAF values show a negative correlation with dizziness handicap inventory (DHI) scores at initial visit (W0). Seed-based FC analysis using the seeds from differential clusters of fALFF, ALFF, and PerAF showed reductions between the left precuneus and bilateral occipital lobe, the left precuneus and left paracentral lobule, and within the occipital lobes among patients with BPPV.
CONCLUSION: The spontaneous activity of certain brain regions in the bilateral occipital and frontoparietal lobes of patients with BPPV was reduced, whereas the activity in the cerebellar vermis was increased. Additionally, there were reductions in FC between the precuneus and occipital cortex or paracentral lobule, as well as within the occipital cortex. The functional alterations in these brain regions may be associated with the inhibitory interaction and functional integration of visual, vestibular, and sensorimotor systems. The functional alterations observed in the visual cortex and precuneus may represent adaptive responses associated with residual dizziness.
Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
The proposed study will test the efficacy of an interactive voice response (IVR) and reinforcement learning (RL) supported motivational intervention delivered after an emergency department (ED) visit to participants with recent non-medical OA use who receive an OA in the ED or who are prescribed an OA at ED discharge, compared to enhanced usual care (EUC). In the intervention condition, IVR calls will ask participants to report information about their health and medications using their touch-tone phone, and based on their responses they may receive brief or extended motivational messages during the IVR call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone. Because the most helpful intensity of intervention is unknown and likely to vary between patients, the project will use an artificial intelligence strategy called reinforcement learning (RL). The RL system will continuously "learn" from the success of prior actions in similar situations with similar patients in order to select the action most likely to reduce non-medical opioid use for each participant during each call.

The proposed study will screen \~ 5,600 ED patients to enroll 600 ED participants in the randomized controlled trial (RCT). Participants will be randomized to the intervention condition (n=300) or to EUC (n=300). All participants will be re-assessed at 1, 3 and 6 months post-ED visit for level of non-medical OA use and related outcomes. The RCT will be complemented by qualitative interviews to inform later implementation.
Chlordiazepoxide HCI Capsules are classified by the Drug Enforcement Administration as a schedule IV controlled substance.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving chlordiazepoxide or other psychotropic agents because of the predisposition of such patients to habituation and dependence.
Formulations for oral transmucosal compositions that include clomiphene-like selective estrogen receptor modulators (C-SERMs) in combination with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquid; gel-forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of C-SERMs. Oral transmucosal compositions allow the delivery of C-SERMs directly into the patient's bloodstream, thereby providing high bioavailability of C-SERMs; therefore, required dose is lower.
The invention discloses a preparation method and application of diterpene in gold leaves, wherein the diterpene mainly comprises veratrum variegate poisonous alkane, kaurane and derivatives thereof. Extracting gold leaves by using aqueous alcohol as a solvent, separating and purifying an extracting solution by using a series macroporous resin method, and drying to obtain the diterpene in the gold leaves. The diterpene in the gold leaves is subjected to various chromatographies to obtain a monomer compound. The preparation process can effectively remove impurities such as saccharides, flavonoids, pigments and the like, and obtain the diterpenoid component with higher purity. The process is simple and controllable, and is suitable for industrial production. The invention also discloses the analgesic effect of the total diterpene extract and the monomeric compound of the gold leaves.
A protein microarray, a detection method thereof, a use thereof, and a kit containing the same are provided. The protein microarray includes a carrier with a protein array block on a surface thereof and at least one protein immobilized on the protein array block. The at least one protein includes a spike protein and a nucleocapsid protein, and can bind to a first antibody in a sample to be tested. The kit for detecting virus infection in vitro includes the protein microarray and a second antibody which can bind to the first antibody. A method for detecting virus infection includes the steps of: respectively adding a serum and the second antibody to the protein microarray, and detecting an optical signal. The protein microarray can be used to detect a coronavirus and an influenza virus, and to determine whether a subject is infected by the virus, and the protein microarray can also be used to evaluate the ability of bioformulations to block infection caused by viruses.
BACKGROUND: Even in patients who survive resuscitation through multidisciplinary treatment, minor persistent symptoms can make hospital discharge difficult. Herein, we report a case of myocardial infarction with intractable symptoms following resuscitation, which were successfully treated using Kampo medicine.
CASE PRESENTATION: A 71-year-old man experienced intractable cough and hiccups following resuscitation for acute myocardial infarction. Despite successful invasive treatment for his cardiac condition, the patient's persistent symptoms hindered his recovery and discharge from hospital. The patient was diagnosed with qi and blood deficiency, qi stagnation, and fluid retention, before being prescribed the Kampo medicine "bukuryoingohangekobokuto (BRIHK)". Within days of treatment initiation, his symptoms notably improved, allowing him to be discharged.
CONCLUSION: This case highlights the potential of Kampo medicine for addressing post-resuscitation symptoms that are refractory to conventional treatments, and emphasizes the importance of integrating Kampo medicine with Western medical practices to enhance patient care and quality of life.
Biocidal proteins capable of isolation from seeds have been characterized. The proteins have an amino acid sequence containing the common cysteine/glycine domain of Chitin-binding Plant Proteins but show substantially better activity against pathogenic fungi, a higher ratio of basic amino acids to acidic amino acids, and/or antifungal activity which results in increased hyphal branching. Antimicrobial proteins isolated from  Amaranthus, Capsicum, Briza  and related species are provided. The proteins show a wide range of antifungal activity and are active against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants may be transformed with this DNA. The proteins find agricultural or pharmaceutical application as antifungal or antibacterial agents. Transgenic plants expressing the protein will show increased disease resistance.
Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
Glycosylphosphatidylinositols (GPIs) are a type of glycolipid responsible for anchoring many important proteins to the cell membrane surface. Defects in the synthesis of GPIs can lead to a group of multisystem disorders known as the inherited GPI deficiencies (IGDs). Homozygosity for the c.-270C > G variant in the promoter of PIGM has been associated with a IGD subtype known as glycosylphosphatidylinositol biosynthesis defect-1 (GPIBD1). The several cases reported in the literature have been described to have a milder neurologic phenotype in comparison to the other IGDs and have been treated with sodium phenylbutyrate with some degree of success. These patients typically present with portal and hepatic vein thrombosis and mostly develop absence seizures. Here we describe a patient homozygous for a nonsynonymous variant in PIGM who deceased at 9 weeks of life and had multiple physical dysmorphisms (rocker bottom feet, midline cleft palate, thickened and lichenified skin), portal vein thrombosis, CNS structural anomalies (progressive multicystic encephalomalacia and ventriculomegaly), and a neurological phenotype of a diffuse encephalopathy. This is the first known case report of a PIGM-related IGD/CDG due to a coding variant.
The present invention relates to methods for the modulation of biofilm formation and antibiotic resistance. Specifically, the present invention identifies the differential expression of biofilm-associated genes in biofilms, relative to their expression in non-biofilm producing bacterial cells. The present invention also identifies the differential expression of biofilm-associated genes in biofilms treated with antibiotic, relative to their expression in untreated biofilms. The present invention describes methods for the diagnostic evaluation of biofilm formation. The invention also provides methods for identifying a compound capable of modulating biofilm formation and antibiotic resistance. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of biofilm-associated diseases or disorders.
Parent questionnaires and sleep characteristics of children (actigraphy and parent report) will be collected at three-time points- Time 1, 2, and 3. Time 1 is the first Baseline Data Collection for the Control Group and Intervention Group, and these data will be collected before the intervention group starts the 3-week intervention. Between Time 1 and Time 2, the Intervention Group will receive the 3-week intervention at the childcare center.
PURPOSE: A therapeutic agent for treatment of disease associated with diabetes mellitus containing the extract of Artemisia capillaris Thunb. possessing blood-glucose lowering activity is provided. It can be used as a therapeutic agent for the treatment of disease associated with a metabolic syndrome such as diabetes mellitus, or a preventive and therapeutic agent for complications associated with diabetes. CONSTITUTION: The therapeutic agent for treatment of disease associated with diabetes mellitus contains the extract of Artemisia capillaris Thunb. The Artemisia capillaris Thunb. extract is prepared by extracting Artemisia capillaris Thunb. in water, methanol or ethanol and then fractioning the crude extract with lower alcohol, acetone or a nonpolar solvent. The lower alcohol is selected from butyl alcohol, propyl alcohol and isopropyl alcohol. The nonpolar alcohol is ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, hexane and methylethyl ketone. The extract of Artemisia capillaris Thunb. contains 30 to 60% and 1 to 3% by weight of capillarisin.
Disclosed in the present invention is a modified nonapeptide, which is an alkyl acylated and/or phosphorylated nonapeptide. The amino acid sequence of the alkyl acylated nonapeptide is sequence I: R-Co-Trp-Ala-Gly-Gly-Phe-Ala-Ser-Gly-Glu, wherein R is a straight-chain or branched chain alkane containing 1-18 carbon atoms. The amino acid sequence of the phosphorylated nonapeptide is sequence II: Trp-Ala-Gly-Gly-Phe-Ala-Ser(PO3H)-Gly-Glu. The amino acid sequence of the alkyl acylated and phosphorylated nonapeptide is sequence III: R-CO-Trp-Ala-Gly-Gly-Phe-Ala-Ser(PO3H)-Gly-Glu, wherein R is a straight-chain or branched chain alkane containing 1-18 carbon atoms. The sleep-inducing activity of the modified nonapeptide of the present invention is higher than the activity of the δ-sleep-inducing peptide (DSIP) which is the strongest in sleep-reducing activity in known peptides, and the duration of action is longer. Moreover, it can antagonize diseases such as anxiety and depression efficiently.
INTRODUCTION: Sudden infant death syndrome (SIDS) is the unexpected death of an infant less than 1 year old, which occurs without presentation of any signs of mortality risk and it is not explained even after investigation, necropsy and review of the site of death. The nurse is an essential healthcare professional working with children and families who can contribute to preventing avoidable deaths of infants. Because SIDS is preventable, permanent education of the healthcare team, family members and infant caregivers is necessary.
OBJECTIVE: To explore the scientific literature about knowledge, attitudes and practice on SIDS.
METHODS AND ANALYSIS: A scoping review will be conducted. Quantitative or qualitative primary studies, theses, dissertations and technical and governmental documents in English, Spanish, French or Portuguese will be considered, without a time limit for selection with search, in the databases: Pubmed, Embase, Scopus, Virtual Health Library, Digital Library of Theses and Dissertations of the Brazilian Institute and Cochrane. A search strategy will be elaborated with the keywords in the following themes: knowledge, attitudes, practice, sudden infant death and healthcare. The eligibility criteria will be applied to references of selected articles to identify new studies. The studies selected will be subjected to thematic content analysis, which allows data interpretation through a systematic classification process for coding themes to the analysis of quantitative and qualitative studies and meta-aggregation. NVIVO V.14 software will be used to organise, code and validate the data.
ETHICS AND DISSEMINATION: Ethics approval is not required. The results will be disseminated to the health science community through professional networks, conference presentations and publication in a scientific journal.
Cervical cancer (CC) and other malignant malignancies are acknowledged to be primarily caused by persistent human papillomavirus (HPV) infection. Historically, vaccinations against viruses that produce neutralizing antibodies unique to the virus have been an affordable way to manage viral diseases. CC risk is decreased, but not eliminated, by HPV vaccinations. Since vaccinations have been made available globally, almost 90% of HPV infections have been successfully avoided. On the lesions and diseases that are already present, however, no discernible treatment benefit has been shown. As a result, therapeutic vaccines that elicit immune responses mediated by cells are necessary for the treatment of established infections and cancers. mRNA vaccines possess remarkable potential in combating viral diseases and malignancy as a result of their superior industrial production, safety, and efficacy. Furthermore, considering the expeditiousness of production, the mRNA vaccine exhibits promise as a therapeutic approach targeting HPV. Given that the HPV-encoded early proteins, including oncoproteins E6 and E7, are consistently present in HPV-related cancers and pre-cancerous lesions and have crucial functions in the progression and persistence of HPV-related diseases, they serve as ideal targets for therapeutic HPV vaccines. The action mechanism of HPV and HPV-related cancer mRNA vaccines, their recent advancements in clinical trials, and the potential for their therapeutic applications are highlighted in this study, which also offers a quick summary of the present state of mRNA vaccines. Lastly, we highlight a few difficulties with mRNA HPV vaccination clinical practice and provide our thoughts on further advancements in this quickly changing sector. It is expected that mRNA vaccines will soon be produced quickly for clinical HPV prevention and treatment.
The present invention is formed of nanoparticles comprising a compound semiconductor containing Ag, In, and Se as components. The peak wavelength of the intensity of light emitted by the light emitter is within the range of 700-1400 nm, and the half-width ΔH of the peak wavelength is 100 nm or less. An Ag-In precursor solution is formulated by dissolving an Ag compound and an In compound in a modifier, and a Se precursor solution is formulated by dissolving Se powder in a solvent. The Se precursor solution is poured into the Ag-In precursor solution heated to, for example, 150°C to prepare a mixture solution. Thereafter, the mixture solution is heated at a reaction temperature of 200°C or more for approximately 30-120 minutes to produce the light emitter. The biological substance-labeling agent includes this light emitter. As a result, a light emitter which can emit intense light in a near-infrared region to allow for detection of a large amount of biological information, and is suitable for bioimaging, a production method therefor, and a biological substance-labeling agent, are obtained.